The pharmaceutical and biotech sectors and high-tech industries are being urged to reach a compromise on patent reform legislation in Congress. Drugmakers are seeking the strongest and longest patent protection, while software and other high-tech companies have different needs. A key congressman said the reforms should not favor one industry over another.

Related Summaries